HHS mylan may have overcharged US epipen 127 billion

The sum is almost 3 times an suggested settlement the business announced in October. Grassley may be the chairman of the Senate Judiciary Committee, that started a probe of epi pen pricing this past year. Mylan failed to need a direct comment.

The Company, that was under passion to get exorbitant cost increases on those apparatus, said in October it decided to repay the U.S. government for $465 million later it had been accused of porting epi-pen together with all the Medicaid Drug Rebate Program being an generic therapy. Mylan, that didn't acknowledge wrongdoing, has said it's still attempting to finalize the compensation.